Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.

The AAPS Journal
Leijun HuJessie L-S Au

Abstract

Suramin, at non-cytotoxic doses, reverses chemoresistance and enhances the activity of mitomycin C (MMC) in mice bearing human bladder xenograft tumors. The present study evaluated the pharmacokinetics of the intravesical suramin and MMC, alone or in combination, in dogs. Animals received either high dose suramin (20 mg/ml), low dose suramin (6 mg/ml), MMC (2 mg/ml), or combination of low dose suramin and MMC, instilled for 2 h. The dosing volume was 20 ml. All groups showed dilution of drug levels over time due to continued urine production. For single agent suramin, the results showed (a) 5% to 10% penetration into bladder tissues, (b) minimal and clinically insignificant systemic absorption (i.e., undetectable at low dose or a peak concentration that was 6,000× lower than urine concentrations), and (c) disproportionally higher drug penetration and concentrations in bladder tissues at the higher dose. Results for single agent MMC are consistent with our earlier observations. The co-administration of MMC did not alter the plasma, urine, or tissue pharmacokinetics of suramin. Adding suramin did not alter plasma or tissue pharmacokinetics of MMC, but lowered the MMC concentrations in urine by about 20%. This may be in part due t...Continue Reading

References

Sep 15, 1989·Biochemical Pharmacology·E L VansterkenburgL H Janssen
Jan 1, 1986·Journal of Clinical Pharmacology·J M CollinsC E Myers
Nov 1, 1994·The Journal of Urology·M M WaltherW M Linehan
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·D SongJ L Au
Jul 13, 2000·Proceedings of the National Academy of Sciences of the United States of America·S SongJ L Au
Apr 20, 2001·Journal of the National Cancer Institute·J L AuUNKNOWN International Mitomycin C Consortium
Aug 2, 2003·BMC Clinical Pharmacology·David G Levitt
Dec 14, 2004·Pharmaceutical Research·Adam OgdenJessie L S Au
Jun 11, 2005·The Journal of Urology·Yan XinJessie L-S Au
Jul 16, 2005·Scandinavian Journal of Urology and Nephrology·Frank G E Perabo, Stefan C Müller
Mar 29, 2008·Pharmaceutical Research·Zancong ShenJessie L-S Au
Jul 18, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A Villalona-CaleroJ L-S Au

❮ Previous
Next ❯

Citations

Dec 22, 2015·The Journal of Urology·Lori Birder
Oct 22, 2016·Urologia·Mauro RagoneseSalvatore M Recupero
Dec 20, 2013·Environmental Technology·Ahmed E M AbdelazizPatrick C Hallenbeck
May 26, 2017·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Andrew S MikhailBradford J Wood

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.